Assessing biomarkers for predicting Alzheimer's disease in TBI patients: A subanalysis of the double‐blinded, phase III randomized clinical trial with biperiden

Abstract

Background: Traumatic Brain Injury (TBI) is a significant risk factor for Alzheimer's Disease (AD). However, the mechanisms connecting TBI to AD pathology remain unclear. Identifying blood‐based biomarkers of neuronal and astrocytic injury is crucial for advancing precision diagnostics and intervention by predicting neurodegeneration.

The paper